Summary: Aetna, a CVS Health company, modified CPB 792 covering human fibrinogen concentrate (RiaSTAP and Fibryga), effective April 29, 2026. Here's what billing teams need to do.
Aetna's fibrinogen concentrate coverage policy under CPB 792 has been updated. This change affects billing for RiaSTAP (fibrinogen concentrate [human]) and Fibryga (fibrinogen [human], lyophilized powder for reconstitution)—two products used to treat acute bleeding episodes in patients with congenital fibrinogen deficiency. The policy does not list specific CPT or HCPCS codes in the available data, so your billing team should pull the current CPB 792 document directly from Aetna to confirm which codes apply to your claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Human Fibrinogen Concentrate (RiaSTAP and Fibryga) — CPB 792 |
| Policy Code | CPB 792 |
| Change Type | Modified |
| Effective Date | April 29, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Coagulation, Hospital Medicine, Critical Care, Interventional Radiology |
| Key Action | Pull the updated CPB 792 document and verify that your prior authorization workflows and medical necessity documentation match the revised criteria before submitting claims dated April 29, 2026 or later. |
Aetna Human Fibrinogen Concentrate Coverage Criteria and Medical Necessity Requirements 2026
Aetna's coverage policy for human fibrinogen concentrate has historically been narrow by design. These are expensive specialty biologics—RiaSTAP and Fibryga both carry significant per-vial costs—and Aetna applies strict medical necessity criteria before approving reimbursement.
The core clinical framework for CPB 792 centers on congenital fibrinogen deficiency, a rare bleeding disorder. Coverage has been tied to documented diagnosis, confirmed low fibrinogen levels, and an active bleeding episode or perioperative management need. Aetna does not broadly cover fibrinogen concentrate for all coagulopathies—the diagnosis must be specific.
Prior authorization is the rule here, not the exception. Given the cost profile of RiaSTAP and Fibryga, expect Aetna to require prior auth on every claim. If your team is billing these products without prior authorization in place, you are looking at automatic claim denial regardless of clinical appropriateness.
Because the available policy data for this update does not include the full revised criteria text, you must pull the current CPB 792 document directly from Aetna to see exactly what changed on April 29, 2026. The fact that this is a modification—not a new policy—means the structure of coverage criteria likely shifted in some meaningful way. The change could involve updated fibrinogen level thresholds, new or removed indications, changes to which product (RiaSTAP vs. Fibryga) is covered in which setting, or revised prior authorization requirements.
That ambiguity is the real problem here. A modification to a policy governing a $5,000-to-$10,000-per-dose biologic is not a minor administrative tweak. Your compliance officer and your specialty pharmacy billing team both need to review this before April 29, 2026 claims go out.
Aetna Human Fibrinogen Concentrate Exclusions and Non-Covered Indications
Based on Aetna's historical approach to CPB 792, coverage for fibrinogen concentrate outside of congenital fibrinogen deficiency has been limited. Acquired coagulopathy—even severe, life-threatening cases—has generally not qualified under this policy when fibrinogen concentrate is used as an alternative to cryoprecipitate.
The off-label use question matters here. Fibrinogen concentrate has growing evidence in trauma, major surgery, and postpartum hemorrhage, but Aetna has not treated those applications the same as congenital deficiency. If your facility has been billing Fibryga or RiaSTAP for acquired coagulopathy and getting paid, this policy modification may be the reason that changes.
Any indication not explicitly listed as covered in CPB 792 is effectively non-covered. Don't assume clinical reasonableness translates to Aetna reimbursement. It doesn't—not for this drug class.
Coverage Indications at a Glance
Because the full revised CPB 792 text is not included in the available policy data, the table below reflects the known framework from Aetna's established coverage policy for fibrinogen concentrate. Verify each row against the current policy document before relying on it for billing.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Acute bleeding in congenital afibrinogenemia | Covered (when criteria met) | Not listed in available data | Core covered indication; prior auth required |
| Acute bleeding in congenital hypofibrinogenemia | Covered (when criteria met) | Not listed in available data | Fibrinogen level documentation required |
| Perioperative management in congenital fibrinogen deficiency | Covered (when criteria met) | Not listed in available data | Prior auth required; diagnosis must be congenital |
| Acquired coagulopathy (trauma, surgery, postpartum hemorrhage) | Not covered / Experimental | Not listed in available data | Off-label use; cryoprecipitate typically expected |
| Dysfibrinogenemia with bleeding | Coverage status unclear | Not listed in available data | Review updated CPB 792 text directly |
| Prophylactic use in congenital deficiency | Coverage status unclear | Not listed in available data | Policy may distinguish acute vs. prophylactic use |
Aetna Human Fibrinogen Concentrate Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the updated CPB 792 document before April 29, 2026. Go to Aetna's clinical policy bulletins directly and download the current version of CPB 792. Read it side by side with the prior version. The change type is "modified"—something specific shifted. You need to know what. |
| 2 | Audit your prior authorization process for both RiaSTAP and Fibryga. If your facility uses either product, confirm that prior auth is in place for every pending and upcoming case. Human fibrinogen concentrate billing without prior authorization is a straight path to claim denial. Don't wait for a remittance to tell you. |
| 3 | Verify the diagnosis codes attached to your fibrinogen concentrate claims. Aetna's medical necessity criteria for CPB 792 are diagnosis-specific. Congenital fibrinogen deficiency requires the right ICD-10-CM codes. If your coders are using acquired coagulopathy codes, those claims will not hold up under this coverage policy. |
| 4 | Check which product—RiaSTAP or Fibryga—your Aetna contract covers. These are two distinct biologics. Some payer policies treat them interchangeably; others do not. The CPB 792 modification may have changed how Aetna distinguishes between them. Confirm this before you have a denial based on product-level coverage rules. |
| 5 | Review claims submitted after April 29, 2026 for consistency with the new criteria. If the modification tightened coverage, claims that would have paid under the old policy may not pay under the new one. Flag any fibrinogen concentrate claims in your AR queue and compare them against the updated CPB 792 billing guidelines. |
| 6 | Loop in your compliance officer if your facility bills fibrinogen concentrate for off-label indications. If your trauma program or obstetrics team has been using Fibryga or RiaSTAP for acquired coagulopathy, this policy change may directly affect your reimbursement. That's a conversation your compliance officer and medical director need to have before the effective date—not after. |
| 7 | Update your charge capture and clinical documentation templates. Whatever changed in CPB 792 on April 29, 2026, it likely requires specific documentation. Make sure your clinical teams know what Aetna needs to see in the record to support medical necessity for these claims. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Human Fibrinogen Concentrate Under CPB 792
The available policy data for this CPB 792 modification does not include specific CPT, HCPCS Level II, or ICD-10-CM codes. This is a limitation of the available data—not a reflection of the policy itself.
Do not assume this means the policy has no code-level implications. Human fibrinogen concentrate products like RiaSTAP and Fibryga are billed under specific HCPCS codes, and those codes are the mechanism by which Aetna processes and adjudicates these claims. You need to confirm the exact codes from the source document.
Action required: Access CPB 792 directly at Aetna's Clinical Policy Bulletins page and document every CPT, HCPCS, and ICD-10 code listed. Add those codes to your charge capture and prior authorization checklists before April 29, 2026.
If you have a specialty pharmacy billing team or work with a pharmacy benefit manager for these products, pull them into this review. Fibrinogen concentrate billing often sits at the intersection of medical benefit and pharmacy benefit coverage, and CPB 792 modifications can shift which benefit pathway Aetna expects you to use.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.